Anti-double-stranded DNA antibody (Anti-dsDNA) (Anti-dsDNA)

Anti-double-stranded DNA (anti-dsDNA) antibodies are a specialized group of antinuclear autoantibodies that target the double-helical structure of deoxyribonucleic acid. They are a hallmark of Systemic Lupus Erythematosus (SLE), with a specificity approaching 95-100% for the condition, making them a primary diagnostic marker (StatPearls, 2023). Pathologically, these antibodies contribute to organ damage, particularly in the kidneys, by forming immune complexes that deposit in the glomerular basement membrane and trigger the complement cascade (Journal of Autoimmunity, 2018). Clinical management of SLE often involves monitoring anti-dsDNA titers, as rising levels frequently precede disease flares and the onset of lupus nephritis. While direct neutralization of these antibodies has been explored with agents like abetimus sodium, current therapeutic approaches primarily focus on reducing their production by targeting B-cell survival factors such as B-lymphocyte stimulator (BLyS) or by depleting B-cells using monoclonal antibodies against CD20 (Nature Reviews Rheumatology, 2020). Consequently, these antibodies serve as both a critical biomarker for treatment efficacy and a central focus of immunosuppressive and B-cell-directed therapies.

Other names

Antibodies to double-stranded DNAdsDNA antibodiesAnti-dsDNA autoantibodiesDouble-stranded DNA antibody

Reduction of autoantibody production through B-cell depletion, inhibition of B-cell survival factors (BAFF/BLyS), or induction of B-cell tolerance.